⌕
Immunome · IMNM · Nasdaq
Tenet 49 · Mixed
Compare
$17.18−2.44%At closeTenet 49 · Mixed
$17.18−0.43 (−2.44%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Immunome (IMNM) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

6 figures withheld by our checks. Each blank figure names its reason.

Business engineChoppy: revenue is 50% below its peak, net margin −3060.0%. Worth your attention in FY25: Share count (+49.0%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▼23.2%
6.9
FY21→FY25CAGR —
Net income ($M)▲27.5%
−212.4
FY21→FY25CAGR —
Free cash flow ($M)▼70.1%
−200.6
FY21→FY25CAGR —
Diluted EPS▲51.4%
−2.43
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+49.0%

58.6mn → 87.4mn diluted shares since FY24. Rising share count dilutes EPS. Growth must outrun it.

Capex
$9.7M

+35.0% YoY in FY25 · 139.5% of revenue.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)6.9Revenue0.0COGS−187.3R&D−43.8SG&A−224.1Op income11.7Tax & other−212.4Net income

-3060¢ of every revenue dollar becomes profit.

Margin trend · direction beats level Operating Net
108530%sector median net margin ~3%FY21FY25

Net margin -3060.0% is below the sector median. This filer reports no gross profit line, so that margin is not drawn.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.7692, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
—6,941.09,041.014,018.00.00.0▼23.2%—
Cost of revenue
—0.00.00.00.00.0——
Gross profit
——A—A—A0.00.0——
Research & development
236,542.0187,286.0281,886.0103,891.023,272.014,110.0▼33.6%+90.9%
Selling, general & admin
64,147.043,768.032,955.019,657.013,629.011,094.0▲32.8%+40.9%
Total operating expenses
300,689.0231,054.0314,841.0123,548.036,901.025,204.0▼26.6%+74.0%
Operating incomefeeds ROC rank
−300,689.0−224,113.0−305,800.0−109,530.0−36,901.0−25,204.0▲26.7%—
Other income, net
18,040.011,719.012,837.02,724.05.0493.0——
Pretax income
−282,649.0−212,394.0−292,963.0−106,806.0−36,896.0−24,711.0▲27.5%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−282,649.0−212,394.0−292,963.0−106,806.0−37,518.0−24,711.0▲27.5%—
Per share
Diluted EPSbuyback-sensitive
−2.65−2.43−5.00−5.38−3.09−2.14▲51.4%—
Diluted shares (mn)
113.5687.3558.6419.8412.1311.54▲49.0%+65.9%
Margins
Gross margin
——A—A—A————
Operating margin
—−3228.8%−3382.4%−781.4%——▲153.5pp−2447.5pp
Net margin
—−3060.0%−3240.4%−761.9%——▲180.4pp−2298.1pp
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
FY19 – FY20 · 2 more years
Unlock the full history →
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-03 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Immunome's revenue last fiscal year?

Immunome reported revenue of $6.9M in fiscal 2025, down 23.2% from fiscal 2024.

What was Immunome's net income?

Immunome reported net income of −$212.4M in fiscal 2025, a net margin of −3060.0%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.